Akero Therapeutics Announces Two Financing Transactions With Pfizer Inc. And Hercules Capital, Inc. Providing Access To Up To $125 Million

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced two financing transactions. The first is a $25 million equity investment by Pfizer Inc. (NYSE: PFE) at $9.90 per share